期刊文献+

药物洗脱支架治疗2型糖尿病合并冠心病多支血管病变的中期疗效 被引量:4

Mid-term result of implantation of drug eluted stent for diabetic patients with multivessel coronary artery lesions
下载PDF
导出
摘要 目的对比分析裸金属支架(BMS)与药物洗脱支架(DES)在2型糖尿病(T2DM)合并多支冠脉病变经皮冠状动脉介入治疗(PCI)应用中的安全性和中期疗效,为DES治疗此类患者提供依据。方法连续入选2002年11月~2005年6月首次接受PCI治疗的443例T2DM合并多支冠脉血管病变患者,其中BMS组226例,雷帕霉素(Cypher)支架组91例,紫杉醇(TAXUS)支架组126例,分析患者住院期间及随访6个月的临床情况。结果三组患者临床特征、手术成功率及住院期间主要不良心脏事件(MACE)发生率等指标均无明显差异。Cypher支架组中病变长度和分叉病变的比例及TAXUS支架组中3支血管和分叉病变的比例均明显高于BMS组(P<0.05或0.01)。两DES组的造影随访再狭窄率明显低于BMS组(Cypher组3.2%、TAXUS组4.5%vsBMS组37.3%,P<0.05),临床随访6个月MACE发生率亦明显低于BMS组(Cypher组5.7%、TAXUS组5.8%vsBMS组18.5%,P<0.01)。结论与BMS相比,T2DM合并多支冠脉血管病变患者植入Cypher支架和TAXUS支架安全性高,6个月中期疗效较理想。 Objective To evaluate the 6-month result of implantation of drug eluted stent (DES) in diabetic mellitus (DM) patients with multivessel coronary artery disease (MVD) to compare with that of bare metal stent (BMS). Methods From November 2002 to June 2005, 443 consecutive T2DM patients with MVD without previous myocardial revascularization underwent successful percutancous coronary intervention (PCI). There were 226 patients in BMS group, 91patients in Cypher stent group, and 126 patients in TAXUS stent group. The results during hospitalization and 6-month clinical follow-up were analyzed among the 3 groups. Results There were no difference in clinical characteristics, PCI success rate, and incidence of in-hospital major adverse cardiac events (MACE) among 3 groups. However, concerning the characteristics of coronary lesions, the rate of bifurcation lesions and lesion length in Cypher stent group and the rates of bifurcation lesions and triple coronary lesions in TAXUS stent group were significantly higher than that in BMS group, respectively (P〈 0. 05 or〈0. 01). Anglographic restenosis occurred less in DES groups than in BMS group (3. 2% in Cypher group and 4. 5%in TAXUS group vs 37. 3% in BMS group, P〈0. 05). Meanwhile, the incidence of MACE at 6-month follow-up period differed significantly between two DES groups and BMS group (5. 7% in Cypher group and 5.8% in TAXUS group vs 18. 5% in BMS group, P〈0. 01). Conclusion As compared with BMS implantation, DES implantation is a safe and efficient PCI procedure with favorable influences on the 6-month proqnosis in T2DM patients with MVD.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2006年第6期518-520,共3页 Medical Journal of Chinese People's Liberation Army
基金 全军"十五"医药卫生科研基金课题资助项目(01Z001)
关键词 糖尿病 2型 冠状动脉疾病 多支血管病变 支架 血管成形术 经腔 经皮冠状动脉 diabetes mellitus, type 2 coronary disease multivessel disease stents angioplasty, transluminal, percutancous coronary
  • 相关文献

参考文献6

  • 1Haffner SM.Coronary heart disease in patients with diabetes.N Engl J Med,2000,342(14):1040.
  • 2Schofer J,Schluter M,Gershlick AH et al.Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coro nary arteries:double-blind,randomised controlled trial (E-SIRIUS).Lancet,2003,362(9390):1093.
  • 3Stone GW,Ellis SG,Cox DA et al.One-year clinical results with the slow release,polymer-based,paclitaxel-eluting TAXUS stent:the TAXUS-Ⅳ trial.Circulation,2004,109(16):1942.
  • 4韩雅玲,王耿,荆全民,王守力,王祖禄,王冬梅,马颖艳,栾波.急性冠状动脉综合征介入治疗4670例近期疗效的评价[J].中华医学杂志,2005,85(15):1040-1044. 被引量:47
  • 5Briguori C,Colombo A,Airoldi F et al.Sirolimus-eluting stent im plantation in diabetic patients with multivessel coronary artery disease.Am Heart J,2005,150:807.
  • 6韩雅玲,王守力,李毅,荆全民,马颖艳,王祖禄,王冬梅,栾波,王效增.急性冠状动脉综合征患者冠状动脉支架术前高负荷量氯吡格雷预治疗近期疗效[J].中国介入心脏病学杂志,2005,13(1):9-12. 被引量:53

二级参考文献24

  • 1Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 288: 2411-2420.
  • 2Chart AW, Molitemo DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tiroffixan and ReoProGive Similar Ettlcacy Outcome Trial (TARGET). J Am CollCardiol, 2003,42:1188-1195.
  • 3Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart, 2001,85:92-93.
  • 4Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) TriM-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patient streated with recombinant tissue plasminogen activator and streptokinase.J Am Coil Cardiol, 1988,11:1-11.
  • 5Biondi-Zoeeai GG, Agostoni P, Testa L, et al. Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose. Evidence from a meta-analysis. Minerva Cardioangiol,2004,52:195-208.
  • 6Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med, 2004,350:232-238.
  • 7Pache J, Kastrati A, Mehilli J, et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.Catheter Cardiovasc Interv, 2002,55:436--441.
  • 8Gawaz M, Seyfarth M, Muller I, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol. 2001. 87 : 332-336.
  • 9Pate GE, Humphries KH, Izadnegahdar M, et al. Population rates of invasive cardiac procedures in British Columbia, 1995 to 2001. Can J Cardiol, 2004,20:712-716.
  • 10Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee on Management Acute Myocardial Infarction). Circulation,1999,100:1016-1030.

共引文献98

同被引文献30

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部